CompletedPhase 4

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

United States16 participantsStarted 2012-11

Plain-language summary

The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival redness

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age \& either sex, any race * Willing and able to follow all instructions * Positive history of ocular allergies * Reproducible positive ocular allergic reaction induced by conjunctival allergen challenge Exclusion Criteria: * Have planned surgery during trial period * Female currently pregnant, planning a pregnancy or lactating * Use of disallowed medications * Have ocular infections, or ocular conditions that could affect study parameters * Have moderate to severe dry eye * Have used an investigational drug or device within 30 days of start of study * Female that is currently pregnant, planning a pregnancy or lactating

What they're measuring

Inflammation Change From Baseline to Day 6

Timeframe: 90 minutes post CAC

Trial details

NCT IDNCT01730872

SponsorORA, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-12

Results submitted2018-12-27

View on ClinicalTrials.gov More Chronic Allergic Conjunctivitis trials